Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edgar T Overton

Showing results (61-70 of 99) with videos related to

Pageof 10
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 2, 2024
Comparison of Two High-Dose Versus Two Standard-Dose Influenza Vaccines in Adult Allogeneic Hematopoietic Cell Transplant RecipientsLora D Thomas, Einas Batarseh, Lubna Hamdan, et al.
Journal of Clinical Pharmacology|June 25, 2021
Pharmacokinetics of Ruxolitinib in HIV Suppressed Individuals on Antiretroviral Agent Therapy from the ACTG A5336 StudySelwyn J Hurwitz, Sijia Tao, Christina Gavegnano, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 7, 2014
Factors associated with delayed hepatitis B viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohortH Nina Kim, Carla V Rodriguez, Stephen Van Rompaey, et al.
The Journal of Infectious Diseases|July 10, 2020
An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency VirusEdgar T Overton, Amy Kantor, Kathleen V Fitch, et al.
AIDS (London, England)|September 16, 2024
Proteinuria and albuminuria among a global primary cardiovascular disease prevention cohort of people with HIVEdgar T Overton, Amy Kantor, Kathleen V Fitch, et al.
Open Forum Infectious Diseases|December 10, 2021
Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency VirusEmma M Kileel, Janet Lo, Carlos Malvestutto, et al.
The Journal of Infectious Diseases|May 10, 2022
Proteomic Signature of Subclinical Coronary Artery Disease in People With HIV: Analysis of the REPRIEVE Mechanistic SubstudyMárton Kolossváry, Chris deFilippi, Michael T Lu, et al.
Open Forum Infectious Diseases|December 10, 2021
A Randomized, Placebo-Controlled Trial Assessing the Effect of VISBIOME ES Probiotic in People With HIV on Antiretroviral TherapyRachel M Presti, Eunice Yeh, Brett Williams, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 30, 2021
Suspected Immune-Related Adverse Events With an Anti-PD-1 Inhibitor in Otherwise Healthy People With HIVCynthia L Gay, Ronald J Bosch, Ashley McKhann, et al.
Plos One|December 6, 2017
Genome-wide admixture and association study of subclinical atherosclerosis in the Women's Interagency HIV Study (WIHS)Aditi Shendre, Howard W Wiener, Marguerite R Irvin, et al.
Pageof 10

Showing results (61-70 of 99) with videos related to

Sort By:
Pageof 10
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 2, 2024
Comparison of Two High-Dose Versus Two Standard-Dose Influenza Vaccines in Adult Allogeneic Hematopoietic Cell Transplant RecipientsLora D Thomas, Einas Batarseh, Lubna Hamdan, et al.
Journal of Clinical Pharmacology|June 25, 2021
Pharmacokinetics of Ruxolitinib in HIV Suppressed Individuals on Antiretroviral Agent Therapy from the ACTG A5336 StudySelwyn J Hurwitz, Sijia Tao, Christina Gavegnano, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 7, 2014
Factors associated with delayed hepatitis B viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohortH Nina Kim, Carla V Rodriguez, Stephen Van Rompaey, et al.
The Journal of Infectious Diseases|July 10, 2020
An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency VirusEdgar T Overton, Amy Kantor, Kathleen V Fitch, et al.
AIDS (London, England)|September 16, 2024
Proteinuria and albuminuria among a global primary cardiovascular disease prevention cohort of people with HIVEdgar T Overton, Amy Kantor, Kathleen V Fitch, et al.
Open Forum Infectious Diseases|December 10, 2021
Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency VirusEmma M Kileel, Janet Lo, Carlos Malvestutto, et al.
The Journal of Infectious Diseases|May 10, 2022
Proteomic Signature of Subclinical Coronary Artery Disease in People With HIV: Analysis of the REPRIEVE Mechanistic SubstudyMárton Kolossváry, Chris deFilippi, Michael T Lu, et al.
Open Forum Infectious Diseases|December 10, 2021
A Randomized, Placebo-Controlled Trial Assessing the Effect of VISBIOME ES Probiotic in People With HIV on Antiretroviral TherapyRachel M Presti, Eunice Yeh, Brett Williams, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 30, 2021
Suspected Immune-Related Adverse Events With an Anti-PD-1 Inhibitor in Otherwise Healthy People With HIVCynthia L Gay, Ronald J Bosch, Ashley McKhann, et al.
Plos One|December 6, 2017
Genome-wide admixture and association study of subclinical atherosclerosis in the Women's Interagency HIV Study (WIHS)Aditi Shendre, Howard W Wiener, Marguerite R Irvin, et al.
Pageof 10